{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:00:12Z","timestamp":1790888412702,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Pathogenesis and Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cpt.2026.04.002","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:33:44Z","timestamp":1776468824000},"page":"349-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond chemotherapy: The rise of nucleic acid nanoformulations in personalized lung cancer therapy"],"prefix":"10.1016","volume":"4","author":[{"given":"Sania","family":"Hermain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshitha","family":"K.S.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavendra Naveen","family":"Nimbagal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpt.2026.04.002_bib1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.cpt.2026.04.002_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.cpt.2026.04.002_bib3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.32604\/or.2023.042863","article-title":"Extensive prediction of drug response in mutation-subtype-specific LUAD with machine learning approach","volume":"32","author":"Jia","year":"2023","journal-title":"Oncol Res"},{"key":"10.1016\/j.cpt.2026.04.002_bib4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajem.2024.02.019","article-title":"Pilot intervention to increase uptake of lung cancer screening through the emergency department","volume":"79","author":"Pettit","year":"2024","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.cpt.2026.04.002_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.colsurfb.2018.08.057","article-title":"Recent insights into the development of nucleic acid-based nanoparticles for tumor-targeted drug delivery","volume":"172","author":"Buddolla","year":"2018","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.cpt.2026.04.002_bib6","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1021\/acsabm.0c00775","article-title":"SiRNA packaged with neutral Cytidinyl\/Cationic\/PEG lipids for enhanced antitumor efficiency and safety in Vitro and in Vivo","volume":"3","author":"Zhou","year":"2020","journal-title":"ACS Appl Bio Mater"},{"key":"10.1016\/j.cpt.2026.04.002_bib7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1089\/nat.2023.0068","article-title":"Nucleic acid therapeutics: successes, milestones, and upcoming innovation","volume":"34","author":"Belgrad","year":"2024","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.cpt.2026.04.002_bib8","article-title":"Multifunctional polymeric micelle-based nucleic acid delivery: current advances and future perspectives","volume":"25","author":"Jarak","year":"2021","journal-title":"Appl Mater Today"},{"key":"10.1016\/j.cpt.2026.04.002_bib9","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.cpt.2026.04.002_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/antib8030041","article-title":"Bispecific t-cell redirection versus chimeric antigen receptor (car)-t cells as approaches to kill cancer cells","volume":"8","author":"Strohl","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.cpt.2026.04.002_bib11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3390\/jnt4030019","article-title":"Recent advances in combating bacterial infections by using hybrid nano-systems","volume":"4","author":"Patel","year":"2023","journal-title":"J Nanotheranostics"},{"key":"10.1016\/j.cpt.2026.04.002_bib12","doi-asserted-by":"crossref","DOI":"10.1007\/s10989-024-10654-2","article-title":"AI-Driven design of cell-penetrating peptides for therapeutic biotechnology","volume":"30","author":"Ma","year":"2024","journal-title":"Int J Pept Res Ther"},{"key":"10.1016\/j.cpt.2026.04.002_bib13","doi-asserted-by":"crossref","first-page":"20529","DOI":"10.1021\/jacs.1c08484","article-title":"Polymers strive for accuracy: from sequence-defined polymers to mRNA vaccines against COVID-19 and polymers in nucleic acid therapeutics","volume":"143","author":"Ishaqat","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.cpt.2026.04.002_bib14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-017-0450-0","article-title":"Advances in the delivery of RNA therapeutics: from concept to clinical reality","volume":"9","author":"Kaczmarek","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.cpt.2026.04.002_bib15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00005-013-0227-0","article-title":"Application of aptamers for targeted therapeutics","volume":"61","author":"Ray","year":"2013","journal-title":"Arch Immunol Ther Exp"},{"key":"10.1016\/j.cpt.2026.04.002_bib16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12032-023-02267-4","article-title":"Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview","volume":"41","author":"Kejamurthy","year":"2024","journal-title":"Med Oncol"},{"key":"10.1016\/j.cpt.2026.04.002_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2026.102896","article-title":"Exosome-like nanovesicles from acerola for CRISPR-Cas9 ribonucleoprotein delivery to the central nervous system","volume":"37","author":"Nagamatsu","year":"2026","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.cpt.2026.04.002_bib18","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.3390\/biomedicines10092179","article-title":"Lipid nanoparticles as delivery vehicles for inhaled therapeutics","volume":"10","author":"Leong","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.cpt.2026.04.002_bib19","article-title":"A CRISPR-Cas12b\u2013Based platform for ultrasensitive, rapid, and highly specific detection of hepatitis B virus genotypes B and C in clinical application","volume":"9","author":"Chen","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.cpt.2026.04.002_bib20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tibtech.2007.09.005","article-title":"Nanoparticles for drug delivery to the lungs","volume":"25","author":"Sung","year":"2007","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.cpt.2026.04.002_bib21","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1039\/C8SM00925B","article-title":"The role of surface charge in the interaction of nanoparticles with model pulmonary surfactants","volume":"14","author":"Mousseau","year":"2018","journal-title":"Soft Matter"},{"key":"10.1016\/j.cpt.2026.04.002_bib22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.molcel.2012.07.029","article-title":"Playing the end game: DNA double-strand break repair pathway choice","volume":"47","author":"Chapman","year":"2012","journal-title":"Mol Cell"},{"key":"10.1016\/j.cpt.2026.04.002_bib23","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/stem.716","article-title":"Concise review: managing genotoxicity in the therapeutic modification of stem cells","volume":"29","author":"Baum","year":"2011","journal-title":"Stem Cell"},{"key":"10.1016\/j.cpt.2026.04.002_bib24","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nmeth.1674","article-title":"Site-specific integration and tailoring of cassette design for sustainable gene transfer","volume":"8","author":"Lombardo","year":"2011","journal-title":"Nat Methods"},{"key":"10.1016\/j.cpt.2026.04.002_bib25","doi-asserted-by":"crossref","first-page":"21312","DOI":"10.1074\/jbc.M114.564625","article-title":"Characterization of genomic deletion efficiency mediated by clustered regularly interspaced palindromic repeats (CRISPR)\/cas9 nuclease system in mammalian cells","volume":"289","author":"Canver","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpt.2026.04.002_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1126\/science.1242088","article-title":"An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level","volume":"342","author":"Bauer","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cpt.2026.04.002_bib27","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.apsb.2020.10.005","article-title":"Small interfering RNA for cancer treatment: overcoming hurdles in delivery","volume":"10","author":"Charbe","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.cpt.2026.04.002_bib28","first-page":"1","article-title":"Delivery systems for siRNA drug development in cancer therapy","volume":"10","author":"Xu","year":"2015","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.cpt.2026.04.002_bib29","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3390\/pharmaceutics17111502","article-title":"Nanoparticles used for the delivery of RNAi-Based therapeutics","volume":"17","author":"Ren","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cpt.2026.04.002_bib30","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1039\/C9TB02764E","article-title":"Stimuli-responsive release and efficient siRNA delivery in non-small cell lung cancer by a poly(l-histidine)-based multifunctional nanoplatform","volume":"8","author":"Shi","year":"2020","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.cpt.2026.04.002_bib31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines-a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cpt.2026.04.002_bib32","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood.V66.5.1149.1149","article-title":"Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes","volume":"66","author":"Ross","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2026.04.002_bib33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/iub.1625","article-title":"RNA sensors of the innate immune system and their detection of pathogens","volume":"69","author":"Chen","year":"2017","journal-title":"IUBMB Life"},{"key":"10.1016\/j.cpt.2026.04.002_bib34","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.cpt.2026.04.002_bib35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11523-020-00717-x","article-title":"MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as new tools for cancer therapy: first steps from bench to bedside","volume":"15","author":"Ratti","year":"2020","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.cpt.2026.04.002_bib36","doi-asserted-by":"crossref","first-page":"6452","DOI":"10.1021\/acs.analchem.2c00401","article-title":"Designing a CRISPR\/Cas12a- and au-nanobeacon-based diagnostic biosensor enabling direct, rapid, and sensitive miRNA detection","volume":"94","author":"Luo","year":"2022","journal-title":"Anal Chem"},{"key":"10.1016\/j.cpt.2026.04.002_bib37","doi-asserted-by":"crossref","first-page":"18691","DOI":"10.1073\/pnas.1415669112","article-title":"A long noncoding RNA connects c-Myc to tumor metabolism","volume":"111","author":"Hung","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cpt.2026.04.002_bib38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2014.05.011","article-title":"Analysis of lncRNA expression profiles in non-small cell lung cancers (NSCLC) and their clinical subtypes","volume":"85","author":"Yang","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cpt.2026.04.002_bib39","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","article-title":"RNA-based therapeutics: an overview and prospectus","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.cpt.2026.04.002_bib40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/gt.2017.8","article-title":"Extracellular vesicles for nucleic acid delivery: progress and prospects for safe RNA-based gene therapy","volume":"24","author":"Jiang","year":"2017","journal-title":"Gene Ther"},{"key":"10.1016\/j.cpt.2026.04.002_bib41","first-page":"67","article-title":"The current status of gene therapy for the treatment of cancer","volume":"15","author":"Belete","year":"2021","journal-title":"Biologics"},{"key":"10.1016\/j.cpt.2026.04.002_bib42","first-page":"36129","article-title":"Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR\/Cas9-mediated genome editing","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cpt.2026.04.002_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2024.342273","article-title":"\u201cDSN-mismatched CRISPR\u2033sensor for highly selective and sensitive detection of under-expressed miR-let-7a","volume":"1295","author":"Qin","year":"2024","journal-title":"Anal Chim Acta"},{"key":"10.1016\/j.cpt.2026.04.002_bib44","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR-Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cpt.2026.04.002_bib45","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12951-022-01477-8","article-title":"Nanoparticle classification, physicochemical properties, characterization, and applications: a comprehensive review for biologists","volume":"20","author":"Joudeh","year":"2022","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.cpt.2026.04.002_bib46","first-page":"106","article-title":"Stimuli-Responsive gene delivery nanocarriers for cancer therapy","volume":"15","author":"Zhang","year":"2023","journal-title":"Nanomicro"},{"key":"10.1016\/j.cpt.2026.04.002_bib47","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2013.05.015","article-title":"Systemic delivery of sticky siRNAs targeting the cell cycle for lung tumor metastasis inhibition","volume":"170","author":"Bonnet","year":"2013","journal-title":"J Controlled Release"},{"key":"10.1016\/j.cpt.2026.04.002_bib48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.semcdb.2017.03.001","article-title":"Extracellular vesicles in lung cancer\u2014From bench to bedside","volume":"67","author":"Kadota","year":"2017","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.cpt.2026.04.002_bib49","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/cancers13040804","article-title":"Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on treatment of the most important actionable oncogenic driver alterations","volume":"13","author":"K\u00f6nig","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cpt.2026.04.002_bib50","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.23.00013","article-title":"Antibody-Drug conjugates in lung cancer: recent advances and implementing strategies","volume":"41","author":"Passaro","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpt.2026.04.002_bib51","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1080\/17425247.2018.1547280","article-title":"Lung cancer: active therapeutic targeting and inhalational nanoproduct design","volume":"15","author":"Alhajj","year":"2018","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.cpt.2026.04.002_bib52","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.7150\/thno.17573","article-title":"Lung cancer-targeting peptides with multi-subtype indication for combinational drug delivery and molecular imaging","volume":"7","author":"Chi","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.cpt.2026.04.002_bib53","article-title":"Stimuli-responsive antibacterial materials: molecular structures, design principles, and biomedical applications","volume":"9","author":"Wang","year":"2022","journal-title":"Adv Sci"},{"key":"10.1016\/j.cpt.2026.04.002_bib54","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1246\/cl.151176","article-title":"Endogenous stimuli-responsive nanocarriers for drug delivery","volume":"45","author":"Chen","year":"2016","journal-title":"Chem Lett"},{"key":"10.1016\/j.cpt.2026.04.002_bib55","doi-asserted-by":"crossref","first-page":"114146","DOI":"10.18632\/oncotarget.23009","article-title":"Cell-surface marker discovery for lung cancer","volume":"8","author":"Cohen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cpt.2026.04.002_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114081","article-title":"Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation","volume":"181","author":"Afonin","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.cpt.2026.04.002_bib57","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2001-1326-2-14","article-title":"Mapping the translational science policy \u2018valley of death\u2019","volume":"2","author":"Meslin","year":"2013","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.cpt.2026.04.002_bib58","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jscs.2012.12.009","article-title":"Advanced drug delivery systems: nanotechnology of health design A review","volume":"18","author":"Safari","year":"2014","journal-title":"J Saudi Chem Soc"},{"key":"10.1016\/j.cpt.2026.04.002_bib59","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2174\/1389200219666180305145345","article-title":"Formulations, pharmacodynamic and clinical studies of nanoparticles for lung cancer therapy - an overview","volume":"19","author":"Zheng","year":"2018","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.cpt.2026.04.002_bib60","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.nano.2014.04.003","article-title":"Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer","volume":"10","author":"Gaur","year":"2014","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"8_Supplement_2","key":"10.1016\/j.cpt.2026.04.002_bib61","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT013","article-title":"Abstract CT013: Phase I trial evaluating BNT116, a TAA-encoding mRNA vaccine, in combination with cemiplimab in frail patients with advanced non-small cell lung cancer (NSCLC) [abstract]","volume":"85","author":"Dziadziuszko","year":"2025","journal-title":"Cancer Res."},{"issue":"16_suppl","key":"10.1016\/j.cpt.2026.04.002_bib62","article-title":"Phase 1\/2 study of mRNA-4359 administered alone and in combination with immune checkpoint blockade in adult participants with advanced solid tumors [abstract]","volume":"41","author":"Sullivan","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.cpt.2026.04.002_bib63","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ssu.10039","article-title":"Translational research in lung cancer","volume":"21","author":"Chen","year":"2003","journal-title":"Semin Surg Oncol"},{"key":"10.1016\/j.cpt.2026.04.002_bib64","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3389\/fonc.2020.01256","article-title":"The therapeutic potential of DNA damage repair pathways and genomic stability in lung cancer","volume":"10","author":"Burgess","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.cpt.2026.04.002_bib65","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1373\/clinchem.2017.271619","article-title":"Technical stability and biological variability in micrornas from dried blood spots: a lung cancer therapy-monitoring showcase","volume":"63","author":"Kahraman","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.cpt.2026.04.002_bib66","first-page":"985","article-title":"Nanomedicine redefining cancer therapeutics: the evolution of precision drug delivery systems","volume":"6","author":"Mehboob","year":"2023","journal-title":"Pak Biomed J"},{"key":"10.1016\/j.cpt.2026.04.002_bib67","first-page":"105","article-title":"Large language models and multimodal foundation models for precision oncology","volume":"8","author":"Truhn","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.cpt.2026.04.002_bib68","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/jps.22243","article-title":"Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics","volume":"100","author":"Xu","year":"2011","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.cpt.2026.04.002_bib69","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.addr.2017.07.015","article-title":"Beyond PEGylation: alternative surface-modification of nanoparticles with mucus-inert biomaterials","volume":"124","author":"Khutoryanskiy","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.cpt.2026.04.002_bib70","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.nano.2011.07.009","article-title":"Uptake of nanoparticles by alveolar macrophages is triggered by surfactant protein A","volume":"7","author":"Ruge","year":"2011","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"10.1016\/j.cpt.2026.04.002_bib71","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1016\/j.biomaterials.2009.03.010","article-title":"The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation","volume":"30","author":"Tseng","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.cpt.2026.04.002_bib72","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3389\/fonc.2019.01560","article-title":"Biomimetic nanoparticles camouflaged in cancer cell membranes and their applications in cancer theranostics","volume":"9","author":"Jin","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.cpt.2026.04.002_bib73","article-title":"Nanotechnology in combating biofilm: a smart and promising therapeutic strategy","volume":"13","author":"Mohanta","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cpt.2026.04.002_bib74","first-page":"337","article-title":"A homologous and molecular dual-targeted biomimetic nanocarrier for EGFR-related non-small cell lung cancer therapy","volume":"27","author":"Xu","year":"2023","journal-title":"Bioact Mater"},{"key":"10.1016\/j.cpt.2026.04.002_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/bdd.70016","article-title":"Integration of data-driven techniques in nanomedicines to address diagnosis and drug delivery strategy for therapy","volume":"46","author":"Girigoswami","year":"2025","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.cpt.2026.04.002_bib76","doi-asserted-by":"crossref","first-page":"485","DOI":"10.14348\/molcells.2021.0042","article-title":"Integrative multi-omics approaches in cancer research: from biological networks to clinical subtypes","volume":"44","author":"Heo","year":"2021","journal-title":"Mol Cells"},{"key":"10.1016\/j.cpt.2026.04.002_bib77","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/ht7040033","article-title":"From single level analysis to multi-omics integrative approaches: a powerful strategy towards the precision oncology","volume":"7","author":"Cantafio","year":"2018","journal-title":"High Throughput"},{"key":"10.1016\/j.cpt.2026.04.002_bib78","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.2174\/0929867043363703","article-title":"ET-18-OCH3 (Edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of fas\/CD95 death receptor","volume":"11","author":"Mollinedo","year":"2004","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.cpt.2026.04.002_bib79","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10147-006-0583-4","article-title":"Biological and clinical implications of EGFR mutations in lung cancer","volume":"11","author":"Mitsudomi","year":"2006","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.cpt.2026.04.002_bib80","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3390\/cancers11050605","article-title":"The function of non-coding RNAs in lung cancer tumorigenesis","volume":"11","author":"Braicu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cpt.2026.04.002_bib81","first-page":"199","article-title":"Current applications and future perspectives of CRISPR-Cas9 for the treatment of lung cancer","volume":"15","author":"Tiruneh","year":"2021","journal-title":"Biologics"}],"container-title":["Cancer Pathogenesis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713226000236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713226000236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:27:02Z","timestamp":1790886422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949713226000236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2949713226000236"],"URL":"https:\/\/doi.org\/10.1016\/j.cpt.2026.04.002","relation":{},"ISSN":["2949-7132"],"issn-type":[{"value":"2949-7132","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond chemotherapy: The rise of nucleic acid nanoformulations in personalized lung cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Pathogenesis and Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpt.2026.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Medical Association (CMA).","name":"copyright","label":"Copyright"}]}}